Is EW a good stock to buy?
Edwards Lifesciences Corporation · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 33
- MAs4 of 4
- MA20×50Golden 10d ago
- MACD1.23
- Sector▲ +15.9%
- Earnings in88d
- P/E60.5x
- Support-11.9%
- Off 52w high-0.5%
- Volume0.8x
- Bollingerupper half
- News0.00
- FCF yield+2.3%
- Trendsideways
- 52w range$75–$108
- ATR+2.7%
- Off ATH-18.7%
- PT$105.21 -1.8%
- P/E vs own+27.5%
- P/E vs sector+87.9%
- Insiders-$10.89M
- RSI80
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Edwards Lifesciences a good stock to buy?
Edwards Lifesciences is strong on 3 of the 5 questions about the business. The price is high: 60.5 times its earnings, above its 3-year median of 35.8 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage hard to copy
- Economics profits steady
- Execution delivers
- Fragility sturdy
- Price expensive
EW sales growth revenue growth
+4%a year, for the last 3 yearsEdwards Lifesciences' sales grew 4% a year for 3 years, to $6.07B in fiscal 2025.
EW analysts' forecast revenue estimates
+12%the sales they expect next fiscal year, on the lastAnalysts expect Edwards Lifesciences' sales to grow 12% to $6.82B in fiscal 2026 (20 analysts).
EW competitors
pretickt analysis+13%its sales in 12 months, on a year before
Edwards Lifesciences' sales grew 13% in the 12 months to Sep 30, 2026, faster than Dexcom (+13%), Boston Scientific (+9%), Stryker (+8%) and GE HealthCare (+2%).
EW sales by business revenue by segment
74%of its sales from Transcatheter Heart ValvesTranscatheter Heart Valves brought Edwards Lifesciences 74% of its sales in fiscal 2025; Surgical Heart Valve Therapy 17%.
EW margin on each sale gross margin
78%left after making the productEdwards Lifesciences kept 78% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 64%.
EW cash generated free cash flow
$1.42Bcash left after investing, last 12 monthsEdwards Lifesciences generated $1.42B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.
EW earnings vs estimates
7 of 8quarters above the analysts' estimateEdwards Lifesciences beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Nov 4, 2026.
EW insider selling
-$34.06Msold, net, by its executives in 12 monthsEdwards Lifesciences' executives and directors sold a net $34.06M of shares in the 12 months to Nov 13, 2026; none bought.
EW number of employees
+1%more people in a yearEdwards Lifesciences had 16,000 employees at the end of fiscal 2025, 1% more than a year before.
EW CEO pay
$17.45Mfor fiscal 2025, 78% of it in stock and optionsEdwards Lifesciences paid its CEO $17.45M for fiscal 2025, 78% of it in stock and options.
EW financial health Altman Z-score
14.3Altman Z-score, safe above 3Edwards Lifesciences' Altman Z-score is 14.3 (Nov 13, 2026), above 3, where the safe zone starts.
EW quality checks Piotroski score
6 of 9checks passedEdwards Lifesciences passes 6 of the 9 Piotroski checks in the 12 months to Sep 30, 2026; it misses on return on assets, long-term debt and gross margin.
EW biggest customers
under 10%of sales from any one customerNo customer made 10% of Edwards Lifesciences' sales in fiscal 2025.
EW in past recessions
pretickt analysis+1%its sales in the worst oneEdwards Lifesciences' sales grew through each of the last 2 US recessions (2008–09 and 2020).
EW price vs profit P/E ratio
60.5×a year's earningsEdwards Lifesciences' P/E ratio is 60.5 (Nov 13, 2026), above its 3-year median of 35.8.
EW price vs competitors
pretickt analysis60.5×a year's earnings, against its competitorsInvestors pay 60.5 times Edwards Lifesciences' earnings (Nov 13, 2026), more than for Stryker (33.0), Dexcom (32.7), GE HealthCare (21.7) or Boston Scientific (18.8).
EW analysts' target price target
-2%to their average targetAnalysts' average price target for Edwards Lifesciences is $105, 2% below the Nov 13, 2026 close of $107.15.
EW analyst ratings, 90 days
pretickt analysisTruist Securitiesupgrade
In the 90 days to Nov 13, 2026, Truist Securities upgraded Edwards Lifesciences.
EW growth priced in fair value
pretickt analysis+17%a year, for ten years, to be worth the priceAt $107.15 a share, Edwards Lifesciences' free cash flow must grow about 17% a year for ten years to be worth the price (Nov 13, 2026).
What is Edwards Lifesciences' P/E ratio?
Edwards Lifesciences' P/E ratio is 60.5 (Nov 13, 2026), above its 3-year median of 35.8. Investors pay 60.5 times Edwards Lifesciences' earnings (Nov 13, 2026), more than for Stryker (33.0), Dexcom (32.7), GE HealthCare (21.7) or Boston Scientific (18.8).
Who are Edwards Lifesciences' biggest competitors?
pretickt compares Edwards Lifesciences with Boston Scientific, GE HealthCare, Stryker and Dexcom. Edwards Lifesciences' sales grew 13% in the 12 months to Sep 30, 2026, faster than Dexcom (+13%), Boston Scientific (+9%), Stryker (+8%) and GE HealthCare (+2%).
Are insiders selling Edwards Lifesciences stock?
Edwards Lifesciences' executives and directors sold a net $34.06M of shares in the 12 months to Nov 13, 2026; none bought.
How does Edwards Lifesciences make money?
Transcatheter Heart Valves brought Edwards Lifesciences 74% of its sales in fiscal 2025; Surgical Heart Valve Therapy 17%.
How many employees does Edwards Lifesciences have?
Edwards Lifesciences had 16,000 employees at the end of fiscal 2025, 1% more than a year before.
Who are Edwards Lifesciences' biggest customers?
No customer made 10% of Edwards Lifesciences' sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.